Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-a106
Abstract: Background: PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. However, there still needs more improvement in efficacy… read more here.
Keywords: inhibitor; idx 1197; brca mutated; parp ... See more keywords